Medical Device Courses Forum - Recent Topics

AI vs Human Judgment in QA : Who Makes the Final Decision ?

Phoenix08 — Wed, 30 Sep 2026 22:26:54 +0000

If an AI system identifies a potential quality issue but a QA professional disagrees with it, who should make the final decision and why ?

Can Product Claims Make Things More Complicated?

Ahmed Elmonier — Sun, 27 Sep 2026 18:35:54 +0000

One thing that caught my attention from this week's lecture was when Dr. Simon talked about how product claims can actually affect the regulatory pathway. I honestly never really thought about that before. I always assumed the pathway mostly depended on what the device is and its risk level.
It made me think though, if a company makes more claims about what their device can do, now they also have more things they need to prove. So at what point does adding another claim actually make the process more complicated than it's worth?
If you were part of the team developing a new device, would you rather start with fewer claims and possibly have an easier path to market, then add more later? Or would you rather try to prove everything the device can do from the beginning?
I'm curious what everyone thinks because I can see an argument for both sides.

Should the corporate veil protect medical device executives?

aysegultinas — Sun, 27 Sep 2026 16:22:26 +0000

One of the main reasons people form a corporation is to protect themselves. The company is treated as its own "person" under the law, so if it gets sued or goes bankrupt, the owners only lose the money they invested. Their personal savings and property stay safe. That's a big part of why people are willing to start risky businesses in the first place.

What bothers me is how this plays out in the medical device industry. A corporation can pay fines, but it can't go to jail, and it can't make decisions on its own. Real people make those decisions. When a device ends up hurting patients, the usual outcome is a settlement or a fine paid by the company, while the people who made the calls often face little personal consequence. So I wonder: is a fine enough to make a company take safety seriously, or is it just treated as part of the budget?

The veil isn't absolute. Elizabeth Holmes from Theranos was sent to prison for defrauding investors about her blood testing technology. But fraud is the easy case. The harder one is when nobody technically lied, but someone rushed testing to meet a launch date or brushed off early complaints because a recall would cost too much.

Part of me thinks executives in this field should carry more personal risk, since patients' health is on the line. On the other hand, if founders knew they could lose everything personally, a lot of them might never start a device company, and fewer new treatments would reach patients.

What do you think is the right balance? Should medical device leaders be held to a higher personal standard than executives in other industries, or would that end up hurting innovation more than it helps safety?

Regulatory Classification of Novel Devices

AndrewG — Sun, 27 Sep 2026 14:34:04 +0000

As we learned in this weeks lecture, all new products that are not substantially equivalent to a predicate device are categorized in Class 3 until proven to belong to a lower class. From a safety perspective this is an understandable standard for the FDA, as requiring all devices go through the most rigorous testing minimizes patient risk.

Conversely, this default classification can slow down innovation, forcing device developers to either treat their lower risk devices as Class 3,go through the process of proving lower risk, or limiting their designs to those equivalent to predicate devices. These added steps require significant resources, increasing the barrier to entry for novel devices. This could push companies to only pursue lower class designs if they can relate them to a predicate device, limiting innovations that could lead to better medical devices.

All things considered, do you think the the FDA should keep their policy of classifying all novel devices as Class 3, or should their be an easier way for companies to make novel, lower class medical devices?

Should AI-Based Medical Devices Require the Same Regulatory Approach as Traditional Medical Devices ?

Phoenix08 — Fri, 25 Sep 2026 02:31:49 +0000

With the growing prevalence of artificial intelligence in medical devices, an intriguing question about the regulation of such devices arises. With traditional medical devices, companies have a fixed design and performance profile from the get-go, making it easier to test them before they hit the market. Some medical devices powered by AI, however, have models that change as new data streams flow in.

Thus, is the existing regulatory framework sufficient for the regulation of AI powered medical devices ? If an AI model has been authorized or cleared, should a company be required to seek approval again before rolling out every update ?

On the one hand, it may take longer for an updated medical device to reach patients if every single update of its AI system is subject to a full regulatory review.

Quality Assurance vs. Quality Control

ha572 — Wed, 23 Sep 2026 14:36:11 +0000

One thing I found interesting was the difference between quality assurance and quality control. Quality assurance is more preventive and focuses on the methods and systems used to make sure a product meets requirements, while quality control evaluates the results against acceptance criteria to determine whether something should be accepted or rejected. I think having both is important because finding a problem after a product is finished is different from preventing the problem from happening in the first place. Why do you think companies might sometimes focus more on quality control instead of preventing problems through quality assurance?

Role of Regulatory Affairs

ha572 — Tue, 22 Sep 2026 14:14:04 +0000

Before this lecture, I assumed Regulatory Affairs mainly handled paperwork after a product was developed. I was surprised to learn that regulatory professionals are involved from the beginning of product development by helping determine product claims, communicating with the FDA, and selecting the correct regulatory pathway. They also continue working after the product reaches the market by managing labeling, maintaining documentation, and supporting inspections. This showed me that Regulatory Affairs is much more involved than I originally thought and plays an important role in ensuring products remain safe and compliant throughout their entire lifecycle. Which responsibility of the Regulatory Affairs department do you think is the most important for protecting patients, and why?

Predicate Devices and the 510(k) Process

ha572 — Tue, 22 Sep 2026 14:13:48 +0000

I thought the 510(k) pathway was interesting because manufacturers do not always have to prove that their device is completely new. Instead, they must show that it is substantially equivalent to a predicate device that is already on the market. This seems like an efficient process because it avoids repeating unnecessary testing for devices that are very similar to existing products while still requiring evidence that they are safe and perform as intended. At the same time, I can see why completely new technologies would require the PMA pathway since there is no previous device to compare them with. Do you think the 510(k) process encourages innovation, or do you think companies are more likely to make small improvements instead of creating entirely new devices?

Medical Device Classification

ha572 — Tue, 22 Sep 2026 14:13:26 +0000

One topic that I found interesting was how medical devices are divided into Class I, II, and III depending on the level of risk they pose to patients. It makes sense that a tongue depressor would not require the same level of review as a life-supporting implant because the potential risks are very different. I think this classification system allows the FDA to focus more attention on devices that could have a greater impact on patient safety while still allowing lower-risk devices to reach the market efficiently. It also shows why understanding a device's intended use is so important early in the design process. Do you think there are any devices that should be moved into a different classification as technology continues to advance?

ISO 10993 and Testing

ha572 — Tue, 22 Sep 2026 14:09:11 +0000

The section on ISO 10993 made me realize how important it is to have a structured approach to testing medical devices. The slides explain that devices should be evaluated based on factors such as the materials used, previous clinical data, chemical composition, exposure, manufacturing processes, and potential biological hazards. I also thought it was interesting that a device may need to be reevaluated if its materials, processing, or sterilization methods change. This makes sense because even a small change in how a device is made could potentially change how the body responds to it.